Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary - Innate Immune, Inc...
October 01 2020 - 8:00AM
Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE
American: DSS), a multinational company operating businesses
focusing on brand protection technology, blockchain security,
direct marketing, healthcare, real estate, and securitized digital
assets, today announced its wholly owned subsidiary Impact
BioMedical, Inc. (“Impact BioMedical”) has formed a new wholly
owned subsidiary, Innate Immune, Inc. (“Innate Immune”), to
initiate efficacy testing of a pan-coronavirus vaccine, a special
type of vaccine designed to protect against multiple coronaviruses.
“Highly pathogenic human coronaviruses are
continuously emerging and remain a major threat to human health,”
stated Daryl Thompson, Impact BioLife’s Director of Scientific
Initiatives and founder of advanced research company GRDG Sciences,
LLC (“GRDG”). Impact BioLife is a wholly owned subsidiary of Impact
BioMedical. “Our pan-coronavirus vaccine is designed to allow us to
not only protect against COVID-19, which is likely here to stay,
but also allow for us to quickly respond to any outbreaks of a
virus of this type in the future.”
Coronaviruses are a large family of viruses and
are common throughout the world. There are currently seven known
human coronaviruses that can make people sick. Common human
coronaviruses, including types 229E, NL63, OC43, and HKU1, usually
cause mild to moderate upper-respiratory tract illnesses, while
MERS-CoV, SARS-CoV, and now SARS-CoV2 can cause more severe
pulmonary diseases.
“COVID-19 has already cost more than one million
lives and continues to disrupt the $133 trillion global economy,”
commented Jason Grady, COO of DSS. “A successful pan-coronavirus
vaccine could save countless lives while lessening or even
preventing the types of disruptions we have seen this year that
have impacted nearly everyone on the planet.”
Innate Immune’s orally delivered pan-coronavirus
vaccine has a well demonstrated safety profile and is designed to
quickly be scaled for global distribution, ease of manufacturing,
and high degree of stability. Innate Immune has gathered a globally
recognized team of virologists to complete the research necessary
to bring this vaccine to market.
“The need for a solution to COVID-19 and
potential future human coronaviruses is clear. We believe this
vaccine can provide that solution while remaining economically
affordable, ensuring availability across the globe” stated Chan
Heng Fai, Chairman of DSS.
GRDG's Chief Scientific Advisor Dr. Roscoe M.
Moore, Jr., the former United States Assistant Surgeon General and
former Epidemic Intelligence Service Officer at Centers for Disease
Control and Prevention or CDC commented, “This pan-coronavirus
vaccine is designed to boost a human’s innate ability to fight
viruses such as SARS-CoV2 by activating all phases of the human
immune system. If successful, it could allow us to prevent further
deaths and global economic disruptions from coronaviruses.”
GRDG is a specialized research team that focuses
on developing solutions for biodefense under the guidelines of the
Project BioShield Act, Event 201, and Potomac Institute for Policy
Studies.
GRDG performs rapid analysis and research by
using advanced algorithms and the most complete databases in the
world. The team operates in a lean and efficient manner and when
necessary utilizes the top contract research organizations to
deliver solid results that are robust and accurate.
About Impact
BioMedical, Inc.Impact
BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary
of DSS. Impact BioMedical strives to leverage its scientific
know-how and intellectual property rights to provide solutions that
have been plaguing the biomedical field for decades. By tapping
into the scientific expertise of GRDG Sciences, LLC, Impact
BioMedical pledges to undertake a concerted effort in the R&D,
drug discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical
visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational company operating
businesses focused on brand protection technology, blockchain
security, direct marketing, healthcare, real estate, and
securitized digital assets. Its business model is based on a
distribution sharing system in which shareholders will receive
shares in its subsidiaries as DSS strategically spins them out into
IPOs. Its historic business revolves around counterfeit deterrent
and authentication technologies, smart packaging, and consumer
product engagement. DSS is led by its Chairman and largest
shareholder, Mr. Fai Chan, a highly successful global business
veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
billion.
For more information on DSS
visit http://www.dsssecure.com.
Investor Contact:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, but are not limited to,
statements related to the Company's intended use of proceeds and
other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include: risks
relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; risks relating to the results of development
activities; our ability to attract, integrate and retain key
personnel; our need for substantial additional funds; patent and
intellectual property matters; competition; as well as other risks
described in the section entitled "Risk Factors" in the prospectus
and in our other filings with the SEC, including, without
limitation, our reports on Forms 8-K and 10-Q, all of which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations and
beliefs. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
DSS (AMEX:DSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Apr 2023 to Apr 2024